Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 1 35 versus BALZIVA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 1 35 versus BALZIVA 21.
ALYACEN 1/35 vs BALZIVA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
BALZIVA-21 is administered 150 mg orally twice daily.
None Documented
None Documented
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Category C
Category C
Oral Contraceptive
Oral Contraceptive